Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-ASPEN: REGN7508 vs ASA for VTE Prophylaxis After Total Knee Arthroplasty
NCT07213778Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- May 2027
- Countries
- 5
01
Overview
A Phase 3 trial of REGN7508 in venous thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals. Started Nov 2025; status: recruiting.
02
Drugs
REGN7508
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07213778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213778.